PepGen is a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the peptide-mediated delivery of nucleic acid therapeutics. Recognising a deep need for a paradigm shift in genomic medicine, PepGen’s proprietary enhanced delivery oligonucleotides (EDOs) strive to achieve the clinical potential of these therapeutics by providing reliable, safe and efficacious delivery to critical disease targets.
The company's EDO platform demonstrates a potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes, advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022.
PepGen presented data for its novel enhanced delivery oligonucleotide (EDO) platform and therapeutic programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical and Scientific Conference;
A novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating myotonic dystrophy type 1 (DM1)
For more than 70 years, the Muscular Dystrophy Association (MDA) has been committed to saving and improving the lives of children and adults living with muscular dystrophy and related life-threatening diseases. PepGen's novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating Duchenne muscular dystrophy. In addition to the current DM1 and DMD pipeline, PepGen continues to advance additional disease-modifying oligonucleotide therapeutics for other DMD patient populations and other severe neuromuscular and neurological diseases towards clinical development.